Statins inhibit aminoglycoside accumulation and cytotoxicity to renal proximal tubule cells

Biochemical Pharmacology

Volumn 79, Issue 4, 2010, Pages 647-654

  Antoine, Daniel J ^a   Srivastava, Abhishek ^a   Pirmohamed, Munir ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; GERANYLGERANYL PYROPHOSPHATE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID; PRAVASTATIN; RAP1A PROTEIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; DRUG STRUCTURE; ENDOCYTOSIS; ENZYME INHIBITION; IC 50; KIDNEY NECROSIS; KIDNEY PROXIMAL TUBULE; NEPHROTOXICITY; NONHUMAN; OPOSSUM; PRIORITY JOURNAL; PROTEIN PRENYLATION;

AMINOGLYCOSIDES; ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY TUBULES, PROXIMAL; OPOSSUMS;

EID: 71349084184     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.09.021     Document Type: Article

References (40)

1. Tan K.H., Mulheran M., Knox A.J., and Smyth A.R. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med 167 (2003) 819-823
2. Begg E.J., and Barclay M.L. Aminoglycosides - 50 years on. Br J Clini Pharmacol 39 (1995) 597-603
3. Slaughter R.L., and Cappelletty D.M. Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring. Pharmacoeconomics 14 (1998) 385-394
4. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis [update of Cochrane Database Syst Rev. 2001;(3):CD001912; PMID: 11687002]. Cochrane Database Syst Rev 2003:CD001912.
5. Mathews A., and Bailie G.R. Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services. J Clin Pharm Ther 12 (1987) 273-291
6. Moestrup S.K., Cui S., Vorum H., Bregengard C., Bjorn S.E., Norris K., et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clini Investig 96 (1995) 1404-1413 [see comment]
7. Christensen E.I., Moskaug J.O., Vorum H., Jacobsen C., Gundersen T.E., Nykjaer A., et al. Evidence for an essential role of megalin in transepithelial transport of retinol. J Am Soc Nephrol 10 (1999) 685-695
8. Nykjaer A., Dragun D., Walther D., Vorum H., Jacobsen C., Herz J., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96 (1999) 507-515
9. Orlando R.A., Rader K., Authier F., Yamazaki H., Posner B.I., Bergeron J.J., et al. Megalin is an endocytic receptor for insulin. J Am Soc Nephrol 9 (1998) 1759-1766
10. Sousa M.M., Norden A.G., Jacobsen C., Willnow T.E., Christensen E.I., Thakker R.V., et al. Evidence for the role of megalin in renal uptake of transthyretin. J Biol Chem 275 (2000) 38176-38181
11. Nagai J., Tanaka H., Nakanishi N., Murakami T., and Takano M. Role of megalin in renal handling of aminoglycosides. Am J Physiol Renal Physiol 281 (2001) F337-F344
12. Schmitz C., Hilpert J., Jacobsen C., Boensch C., Christensen E.I., Luft F.C., et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem 277 (2002) 618-622
13. Watanabe A., Nagai J., Adachi Y., Katsube T., Kitahara Y., Murakami T., et al. Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists. J Controlled Release 95 (2004) 423-433
14. Brunskill N.J., Cockcroft N., Nahorski S., and Walls J. Albumin endocytosis is regulated by heterotrimeric GTP-binding protein G alpha i-3 in opossum kidney cells. Am J Physiol 271 (1996) F356-F364
15. Malstrom K., Stange G., and Murer H. Identification of proximal tubular transport functions in the established kidney cell line, OK. Biochim Biophys Acta 902 (1987) 269-277
16. Clague M.J. Molecular aspects of the endocytic pathway. Biochem J 336 (1998) 271-282
17. Magee T., and Marshall C. New insights into the interaction of Ras with the plasma membrane. Cell 98 (1999) 9-12
18. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 (1990) 425-430
19. Cordle A., Koenigsknecht-Talboo J., Wilkinson B., Limpert A., and Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280 (2005) 34202-34209
20. Verhulst A., D'Haese P.C., and De Broe M.E. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 15 (2004) 2249-2257
21. Sidaway J.E., Davidson R.G., McTaggart F., Orton T.C., Scott R.C., Smith G.J., et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 15 (2004) 2258-2265
22. Khwaja A., O'Connolly J., and Hendry B.M. Prenylation inhibitors in renal disease. Lancet 355 (2000) 741-744
23. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
24. Heller D.N., Peggins J.O., Nochetto C.B., Smith M.L., Chiesa O.A., and Moulton K. LC/MS/MS measurement of gentamicin in bovine plasma, urine, milk, and biopsy samples taken from kidneys of standing animals. J Chromatogr B Analyt Technol Biomed Life Sci 821 (2005) 22-30
25. McTaggart F., Brown G.R., Davidson R.G., Freeman S., Holdgate G.A., Mallion K.B., et al. Inhibition of squalene synthase of rat liver by novel 3′ substituted quinuclidines. Biochem Pharmacol 51 (1996) 1477-1487
26. Staal A., Frith J.C., French M.H., Swartz J., Gungor T., Harrity T.W., et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 18 (2003) 88-96
27. Brewer Jr. H.B. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 92 (2003) 23K-K29
28. Olsson A.G., McTaggart F., and Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 20 (2002) 303-328
29. Gekle M., Mildenberger S., Freudinger R., Schwerdt G., and Silbernagl S. Albumin endocytosis in OK cells: dependence on actin and microtubules and regulation by protein kinases. Am J Physiol 272 (1997) F668-F677
30. Schwegler J.S., Heppelmann B., Mildenberger S., and Silbernagl S. Receptor-mediated endocytosis of albumin in cultured opossum kidney cells: a model for proximal tubular protein reabsorption. Pflugers Arch 418 (1991) 383-392
31. Gibbons C.E., Maldonado-Perez D., Shah A.N., Riccardi D., and Ward D.T. Calcium-sensing receptor antagonism or lithium treatment ameliorates aminoglycoside-induced cell death in renal epithelial cells. Biochim Biophys Acta 1782 (2008) 188-195
32. Sauvant C., Holzinger H., and Gekle M. Modulation of the basolateral and apical step of transepithelial organic anion secretion in proximal tubular opossum kidney cells. Acute effects of epidermal growth factor and mitogen-activated protein kinase. J Biol Chem 276 (2001) 14695-14703
33. Nielsen R., Birn H., Moestrup S.K., Nielsen M., Verroust P., and Christensen E.I. Characterization of a kidney proximal tubule cell line, LLC-PK1, expressing endocytotic active megalin. J Am Soc Nephrol 9 (1998) 1767-1776
34. Sandoval R.M., Reilly J.P., Running W., Campos S.B., Santos J.R., Phillips C.L., et al. A non-nephrotoxic gentamicin congener that retains antimicrobial efficacy. J Am Soc Nephrol 17 (2006) 2697-2705
35. McTaggart F., Buckett L., Davidson R., Holdgate G., McCormick A., Schneck D., et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87 (2001) 28B-32B
36. Neuvonen P.J., Backman J.T., and Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 47 (2008) 463-474
37. White C.M. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 42 (2002) 963-970
38. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 39 (2000) 397-412
39. Martin P.D., Warwick M.J., Dane A.L., Brindley C., and Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Therap 25 (2003) 2553-2563
40. Steffens S., and Mach F. Drug insight: immunomodulatory effects of statins - potential benefits for renal patients?. Nature Clini Practice Nephrol 2 (2006) 378-387